Hypertension is associated to an increase in central oxidative stress and an attenuation of the baroreflex control of arterial pressure. The present study evaluated the effect of alterations in the levels of nitric oxide (NO) and superoxide anion in the caudal ventrolateral medulla (CVLM), a key area of the brainstem for the baroreflex control of arterial pressure, in renovascular hypertensive rats (2K1C). Baseline mean arterial pressure (MAP), heart rate (HR), and reflex bradycardia were evaluated 30 days after renal artery occlusion in anesthetized (urethane, 1.2 g/kg, i.p.) 2K1C or normotensive (SHAM) rats. The MAP, HR, and baroreflex control of HR were evaluated before and after CVLM microinjections of the non-selective NOS inhibitor L-NAME (10 nmol), the NO precursor L-ARG (50 nmol), or the antioxidant ascorbic acid, Vit C (10 nmol). In both 2K1C and SHAM animals, CVLM microinjection of L-NAME produced a decrease in MAP, whereas L-ARG induced a significant increase in MAP. However, microinjection of Vit C into the CVLM produced a decrease in MAP and HR only in 2K1C and not in SHAM rats. Cardiovascular effects produced by microinjection of L-ARG into the CVLM were abolished by prior microinjection of L-NAME in the CVLM of 2K1C and SHAM rats. Microinjection of L-NAME into the CVLM increased the sensitivity of reflex bradycardia in 2K1C animals. In contrast, the CVLM microinjection of L-ARG reduced reflex bradycardia only in SHAM rats. Vit C in the CVLM did not change reflex bradycardia in either 2K1C or in SHAM rats. These results suggest that increased oxidative stress in the CVLM during hypertension contributes to the reduced baroreflex sensitivity and to maintain hypertension in the 2K1C model. Ó 2012 Elsevier Inc.
Introduction
Evidence supports the hypothesis that the increase in oxidative stress plays a role in the pathophysiology of arterial hypertension [1, 2] . It has been shown that increase in reactive oxygen species (ROS), nitric oxide (NO) and superoxide anion (O 2 À ) may be altered in central areas related to cardiovascular control in hypertensive animals [3, 4] .
NO plays an important role in cardiovascular regulation, in both physiological and pathological conditions [5, 6] . It has been described as a neurotransmitter in the brain, involved in the modulation of excitatory and inhibitory neurons, and acting through interneurons or directly stimulating the release of neurotransmitters [7, 8] . Increasing evidence indicates that NO modulates responses mediated by the sympathetic nervous system (SNS) and parasympathetic nervous system (PNS) through its action in the main areas in the brain involved in the control of cardiovascular functions, such as the paraventricular nucleus of the hypothalamus (PVN) [9] [10] [11] , the nucleus of the solitary tract (NTS) [12, 13] and the areas of the ventrolateral medulla (VLM) [12, 14, 15] . Previous studies have shown that mRNA expression of NO synthase (NOS) isoforms and the NO production in the brain may vary in hypertensive rats, according to the time course of the hypertension 1089-8603 Ó 2012 Elsevier Inc. doi:10.1016/j.niox.2012.01.002
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or the CNS region [12, [16] [17] [18] [19] [20] . Additionally, an elevation of superoxide in brain areas related to cardiovascular control has been described as one of the factors responsible for increased SNS activity in hypertensive models [1, 21] .
The CVLM is a depressor region, and stimulation of this area causes hypotension with consequent vasodilatation of several peripheral vascular beds [22] [23] [24] . The tonic activity of the CVLM is important for the maintenance of normal blood pressure (BP), and involves a combination of excitatory (glutamatergic) and inhibitory (GABAergic) synapses, although the source of this activity is not fully understood [25, 26] . It is well established that CVLM is rich in GABAergic neurons, and many of these GABAergic neurons tonically inhibit sympatho-excitatory neurons in the rostral VLM (RVLM), leading to a decrease in SNS activity and a consequent reduction in BP [27] [28] [29] [30] [31] . Therefore, inhibition of CVLM neuronal activity significantly increases the neuronal activity of RVLM, SNS activity, and BP. Further, the CVLM is essential for most sympatoinhibitory reflexes produced by activation of NTS, such as the baroreflex control of BP [31, 32] .
The contribution of the CVLM to the genesis and maintenance of hypertension has not been completely elucidated [33] [34] [35] . Several studies have shown that hypertension occurs during hyperactivity of neurons in the RVLM [36] [37] [38] . Moreover, in spontaneous hypertensive rats (SHR) and in renovascular hypertensive rats [39, 40] , the inhibition caused by GABAergic CVLM on the RVLM excitatory neurons seems to be attenuated, which could explain the increase in SNS activity observed in these models of hypertension [39] [40] [41] .
In the present study, we evaluated the possibility that NO and the superoxide anion (O 2 À ) could not only contribute to the baseline control of BP, but could also modulate baroreflex bradycardia at the CVLM in hypertensive rats. For this purpose, we evaluated baseline BP and baroreflex control of HR after CVLM microinjection of the non-selective NOS inhibitor L-NAME, microinjection of the NO precursor L-arginine (L-ARG), or microinjection of a potential scavenger of superoxide anions (ascorbic acid -vitamin C; Vit C) in 2K1C renovascular hypertensive rats.
Materials and methods

Animals
Experiments were performed in male Fisher rats from ENUT, Universidade Federal de Ouro Preto, Brazil. The animals were housed in separate cages in groups of four rats according to their group (2K1C or SHAM), with free access to rat chow and tap water in a temperature-and light-controlled room. All animal procedures were in accordance with the Guidelines for Ethical Care of Experimental Animals, and were performed as approved by the Institutional Ethics Committee of the Federal University of Ouro Preto, Minas Gerais, Brazil (Protocol # 022/2007).
Induction of renovascular hypertension
Goldblatt renovascular hypertension was induced as described by Goldblatt et al. [42] . Briefly, the rats (weighing 150-180 g) were anesthetized with a mixture of ketamine and xylazine (50 and 10 mg/kg, respectively, i.p.), and a silver clip (0.20 mm ID) was placed around the left renal artery through a midline incision (Goldblatt renovascular hypertension, 2-kidney, 1-clip model; 2K1C). Other rats were submitted to similar procedures but without the renal-artery clip placement (SHAM group or normotensive rats). BP recording and CVLM microinjections were carried out 30 days after the surgery. At this time the animals weighed 260-300 g.
Arterial pressure measurements
Pulsatile arterial pressure was monitored by a Gould pressure transducer (PM-1000, CWE) coupled to a blood pressure signal amplifier (UIM100A, Powerlab System). Mean arterial pressure (MAP) and heart rate (HR) were determined from the arterial pressure wave. All variables were continuously recorded with a PowerLab digital acquisition system (Powerlab -4/20, AD Instruments) with an 800 Hz sampling rate.
CVLM microinjections
2K1C and SHAM rats were anesthetized with urethane (1.2 g/kg, i.p.) and underwent a tracheostomy. Next, a polyethylene catheter was inserted into the abdominal aorta through the femoral artery, for arterial pressure measurement, and another catheter was inserted into the inferior cava vein through the femoral vein, for drug injection. The animals were placed in a stereotaxic frame (David Kopf Instruments, CA) as described by Rodrigues et al. [43] .
Unilateral microinjections of L-NAME (10 nmol/100 nl), L-ARG (50 nmol/100 nl), Vit C (10 nmol/100 nl) or sterile saline (vehicle -NaCl 0.9%) in a volume of 100 nl were made over a 20-30 s period into the CVLM (0.7 mm anterior, 1.8 mm lateral to the obex, and just above the pia mater on the ventral surface), as described by Alzamora et al. [44] . The doses of L-NAME, L-ARG, and Vit C were based on previous studies [1, 15, 45, 46] .
Evaluation of the sensitivity of the baroreflex bradycardia
The baroreflex bradycardia was tested in different groups of animals (2K1C and SHAM), before and 5-10 min after CVLM microinjections of L-NAME (n = 8 in each group), L-ARG (n = 6-7), and Vit C (n = 10-11). Baroreflex control of HR was determined by recording reflex heart rate changes (baroreflex bradycardia) in response to transient increases in MAP produced by repeated bolus injections of graded doses of phenylephrine (0.5-50 lg, i.v.) in urethane-anesthetized rats, according to previous studies [47] . The HR was converted to pulse interval (PI, ms) by the formula: 60,000/HR. A best-fit regression line was drawn from MAP and HR changes obtained with the different doses of phenylephrine for each animal. The slope of the regression line was used as an index of baroreflex sensitivity (baroreflex gain).
Experimental procedures
The arterial pressure and HR of urethane-anesthetized 2K1C and SHAM rats were continuously recorded. In three different groups of rats, after a 10-min stabilization period, the micropipette was positioned in the CVLM, and L-NAME (10 nmol, n = 6-7) or saline (NaCl, 0.9% -100 nL); L-ARG (50 nmol, n = 6-11) or saline (NaCl, 0.9% -100 nL); and Vit C (10 nmol, n = 13-14) or saline were microinjected, in a random order. In some animals, phosphatebuffered saline (pH 7.4; 100 nl) was microinjected into the CVLM as a control for the Vit C vehicle. In order to test the ability of L-ARG to induce a rise in NO level, approximately 50 min after the CVLM microinjection of the L-ARG, L-NAME was microinjected, and after 5 min L-ARG was repeated in 2K1C (n = 6) or SHAM (n = 11) rats.
Finally, the baroreflex test was evaluated in three additional groups of 2K1C and SHAM animals, before and 5-10 min after CVLM microinjection of L-NAME (n = 8), L-ARG (n = 6-7), or Vit C (n = 10-11).
In another group of rats SHAM and 2K1C rats (n = 6-12) was evaluated the mRNA expression of nNOS and eNOS by qRT-PCR analysis.
Histological verification of microinjection sites
At the end of each experiment, the animals were then killed with an excess of anesthetic, and the brain was carefully removed and fixed in 10% phosphate-buffered formalin. Serial coronal sections (40-50 lm) of the medulla oblongata were made and stained with neutral red for histological examination. Microinjection sites were identified by tissue rupture produced by the microinjections under light microscopy, and was referred to standard anatomical structures of the brain stem according to the atlas of Paxinos and Watson [48] . Fig. 1 shows, on the left side, an image of a histological section of the medulla, illustrating the microinjection site in a representative animal. On the right side, diagrams of frontal sections of the medulla from the atlas of Paxinos and Watson [48] show the location (black area) of the center of the microinjections in all animals of this study. The microinjections into the CVLM were located in the ventral portion of the lateral reticular nucleus, at the level of À13.3 to À13.8 mm, posterior to the bregma (Fig. 1) .
Reverse transcription and real-time PCR
Normotensive -SHAM and 2K1C rats (n = 6-12) were decapitated, their brains were removed, the CVLM region was dissected, quickly frozen on liquid nitrogen and stored at À70°C until processed. A pool of CVLM region from two animals was homogenized, and the total RNA was isolated with TRIzol reagent (Invitrogen Life Technologies) according to the manufacturer's protocol. RNA samples, approximately 2 lg, were treated with DNAse (Invitrogen Life Technologies) to eliminate genomic DNA present in the samples.
Approximately 1 lg of DNased mRNA was used as template for M-MLV reverse transcriptase (Promega) using the reverse specifics oligonucleotides. Real-time PCR was carried out following generation of first strand cDNA. Endothelial (eNOS), neuronal NOS (nNOS) and the endogenous S26 ribosomal cDNA were amplified using specific primers (Table 1) and SYBR Green PCR Master Mix (Applied Biosystems) in an ABI Prism 7000 Sequence Detection Systems.
Drugs
The drugs (urethane, phenylephrine, L-NAME, and L-ARG; Sigma Chemical Company, St. Louis, MO, USA) were all dissolved in saline. Vit C (Sigma Chemical Company, St. Louis, MO, USA) was diluted in phosphate-buffered saline (pH 7.4).
Statistical analysis
The results are expressed as means ± SEM. Comparisons between two groups were assessed by Student's t test. Comparisons of three or more groups were made by one-way ANOVA followed by Newman-Keuls. Statistical analyses were performed with the software Graphpad Prism (version 4.00). The criterion for statistical significance was set at p < 0.05.
Results
Baseline values of MAP and HR
The baseline values of MAP of anesthetized 2K1C (140 ± 2 mm Hg, n = 45) were significantly higher than the baseline values of MAP of anesthetized SHAM rats (105 ± 1 mm Hg, n = 44). The baseline values of HR were not significantly different between the 2K1C group (370 ± 6 beats/min, n = 45) and the SHAM group (372 ± 4 beats/min, n = 44).
BP effect of CVLM microinjections
Unilateral microinjection of L-NAME into the CVLM produced a significant decrease in MAP in 2K1C rats (À17 ± 3 vs À5 ± 1 mm Hg, n = 7; saline; Fig. 2A ), which was similar to that produced by microinjection of L-NAME into the CVLM in SHAM rats (À17 ± 3 vs À4 ± 0.4 mm Hg, saline; n = 6; Fig. 2A ). No significant changes were observed in the duration of the hypotensive effect induced by L-NAME in 2K1C rats (6 ± 1 min, n = 6) or in SHAM rats (4 ± 0.5 min, n = 6). In addition, L-NAME also induced a significant fall in HR in 2K1C rats (À29 ± 7 beats/min vs À1 ± 1 beats/min, n = 7; saline; Fig. 2D ), similar to that observed in SHAM rats (À39 ± 15 beats/min vs À1 ± 1 beats/min, n = 6; saline; Fig. 2D ).
Microinjection of L-ARG into the CVLM produced a significant increase in MAP in 2K1C rats (11 ± 3 vs À0.3 ± 0.6 mm Hg, n = 6; saline; Fig. 2B ), which was similar to the pressor effect produced by microinjection of L-ARG into the CVLM in SHAM rats (11 ± 1 mm Hg, n = 11; Fig. 2B ). However, L-ARG lengthened the hypertensive effect in 2K1C rats (26 ± 7 min, n = 6) compared to the SHAM group (10 ± 2 min, n = 11). The pressor effect of L-ARG was not accompanied by a significant effect on the HR in 2K1C rats (À12 ± 6 vs À3 ± 1 beats/min, n = 6) or in SHAM rats (8 ± 8 beats/ min vs À1 ± 1 beats/min, n = 11; saline; Fig. 2E ).
Microinjection of Vit C into the CVLM produced a significant decrease in MAP in 2K1C rats (À17 ± 2 vs À3 ± 0.5 mm Hg, n = 14; saline; Fig. 2C ). In contrast, microinjection of Vit C into the CVLM produced no significant decrease in MAP in SHAM rats (À5 ± 1 vs À3 ± 0.6 mm Hg, n = 13; saline; Fig. 2C ). Vit C also induced a significant decrease in HR in 2K1C rats (À26 ± 6 beats/min vs À0.5 ± 0.5 beats/min, n = 14 saline; Fig. 2F ) and had no significant effect on HR in SHAM rats (À13 ± 4 beats/min vs À3 ± 2 beats/min, n = 13; saline; Fig. 2F ).
As shown in Fig. 3 , microinjection of L-L-NAME into the CVLM abolished the pressor effect induced by L-ARG on the CVLM in 2K1C rats (11 ± 3 mm Hg, before L-NAME vs 3 ± 2 mm Hg, after L-NAME; n = 6; Fig. 3A ) and in SHAM rats (11 ± 1 mm Hg, before L-NAME vs 3 ± 2 mm Hg, after L-NAME; n = 11; Fig. 3A) . Microinjection of L-ARG after L-NAME had no significant effect on HR in both groups (data not shown).
Evaluation of the sensitivity of the baroreflex bradycardia
As expected, the reflex bradycardia of 2K1C rats (0.12 ± 0.02 ms/ mmHg, n = 25) was significantly lower compared to that of SHAM CGTGCTTCCCAAGCTCTATGT CGATTCCTGACAACCTTGCTATG rats (0.37 ± 0.07 ms/mmHg, n = 25). Fig. 4A illustrates the baroreflex bradycardia induced before and after the CVLM microinjection of L-NAME. As shown in Figs. 4A and 5A, L-NAME significantly increased baroreflex bradycardia in 2K1C rats (0.18 ± 0.04 vs 0.07 ± 0.01 ms/mmHg, n = 8; before L-NAME). In contrast, microinjection of L-NAME into the CVLM did not change the baroreflex bradycardia of the SHAM rats (0.41 ± 0.05 vs 0.35 ± 0.06 ms/mmHg, n = 8, before L-NAME; Fig. 5A ).
On the other hand, L-ARG significantly decreased baroreflex bradycardia in SHAM rats (0.28 ± 0.03 vs 0.42 ± 0.07 ms/mmHg, n = 6; before L-ARG; Figs. 4B and 5B). In contrast, microinjection of L-ARG into the CVLM did not change the baroreflex bradycardia in 2K1C rats (0.08 ± 0.02 vs 0.10 ± 0.03 ms/mmHg, n = 7, before L-NAME; Fig. 5B ).
In addition, microinjection of Vit C into the CVLM did not change the baroreflex bradycardia in 2K1C rats (0.14 ± 0.02 vs 0.13 ± 0.02 ms/mmHg, n = 10, before Vit C; Fig. 5C ) and in SHAM rats (0.34 ± 0.06 vs 0.35 ± 0.06 ms/mmHg, n = 11, before Vit C; Fig. 5C ).
Expression of nNOS mRNA and eNOS mRNA in the CVLM
As shown in Table 2 the mRNA expression of nNOS and eNOS, obtained by qRT-PCR analysis, were lower in the CVLM of 2K1C rats (values and values, respectively) as compared to SHAM rats (values and values, respectively).
Discussion
The main finding of the present study was that CVLM inhibition of NO synthase with L-NAME increased the sensitivity of the baroreflex bradycardia in 2K1C hypertensive rats, suggesting the existence of an inhibitory nitrergic influence on CVLM neurons that participates in baroreflex pathway. Interestingly, the response induced in baseline arterial pressure was not different in 2K1C rats in comparison to SHAM. On the contrary, the administration of an antioxidant agent, Vit C, did not alter baroreflex modulation at the CVLM, but induced a higher hypotensive response in 2K1C rats.
This result is in keeping with those of other studies showing that NO plays an inhibitory role in the brain [49] , especially in areas related to cardiovascular control such as the PVN [9, 10, 49] , NTS [50] [51] [52] , and RVLM [53] [54] [55] . Overall, these studies have shown that an increase in NO level in the PVN or in the RVLM leads to effects that include marked reductions in BP and in sympathetic activity, through an interaction between NO and GABAergic neurons. These studies are consistent with the observations reported here, and reinforce the hypothesis that NO also has an inhibitory role in neurons of the CVLM.
Several studies using a variety of methods have identified NOS in different nuclei associated with baroreflex control, including the PVN, NTS, CVLM, and RVLM [20, [56] [57] [58] . The role of NO in different areas of the brain related to baroreflex control is not completely Mean arterial pressure (DMAP, mmHg) and heart rate (HR, beats/min) changes produced by CVLM microinjections of L-NAME (10 nmol/100 nl; panels A and D) or L-ARG (50 nmol/100 nl; panels B and E) or Vit C (10 nmol/100 nl, panels C and F) or saline (100 nl) in normotensive (SHAM, n = 6-13) or hypertensive (2K1C, n = 6-14) rats. ⁄ p < 0.05 in comparison to saline (ANOVA followed by Newman-Keuls test). Fig. 3 . Mean arterial pressure changes (DMAP, mmHg) produced by CVLM microinjections of L-ARG (50 nmol/100 nl) before and 5 min after microinjection of L-NAME (10 nmol) in normotensive (SHAM, n = 11) or hypertensive (2K1C, n = 6) rats.
⁄ p < 0.05 compared to saline (ANOVA followed by Newman-Keuls test) and # p < 0.05 compared to L-ARG before (ANOVA followed by Newman-Keuls test).
understood. In the NTS, a major site for baroreflex modulation, some investigators have suggested that NO increases baroreflex sensitivity [59] , whereas others have found either that NO mediated an inhibitory effect [17, 60, 61] or that it had no effect [17, 62] . Conversely, studies have shown that the overexpression of eNOS in RVLM improved baroreflex function in stroke-prone SHR [55] , whereas nNOS gene transfer into the RVLM improves baroreflex function in rats with heart failure [63] . These effects may have resulted from a cardiac sympathoinhibitory effect of NO in RVLM neurons. Although it has been shown that NO acts as a modulator of activity of the SNS, studies showed different changes in the mRNA expression of nNOS and eNOS in different areas of the CNS and at different stages or models of hypertension, such as SHR [17, 18, 67] and in 2K1C renovascular hypertensive rats [19] . Our present results showed that the mRNA expression of nNOS and eNOS in the CVLM were lower in 2K1C rats (4 weeks of renal artery occlusion) compared to SHAM rats. In fact, Krukoff et al. [19] showed that nNOS gene expression in CVLM was increased at 3 weeks and decreased at 6 weeks after renal artery occlusion. Plochocka-Zulinska and Krukoff [18] demonstrated an increase in nNOS expression in the CVLM of adult SHR, but not in young pre-hypertensive rats [18] . However, despite of the reduced mRNA levels of NOS found in our study, our data showed an improvement in baroreflex sensitivity after L-NAME microinjection into the CVLM in hypertensive rats, suggesting that NO is playing a modulatory role on baroreflex control at this site. Whether this fact can be attributed to a different source of NO or to an increased activity of the enzymes involved in NO production at this site remains to be investigated. In addition, the relative contribution of each NOS isoform(s) for the production of NO in the CVLM at different stages of hypertension awaits future investigation. In the present study, the use of a non-specific inhibitor of the NOS, L-NAME, as a first approach to understand the involvement of NO in the CVLM, showed that NO acting at the CVLM is contributing to the lower baroreflex sensitivity in renovascular hypertensive rats, at least at a time point where the disease is dependent on the activation of the circulating reninangiotensin system.
Our data showed that microinjection of L-ARG, a precursor for NO synthesis, into the CVLM induced a significant attenuation in baroreflex bradycardia in normotensive rats, which reinforces the hypothesis that increased NO in the CVLM leads to a decrease in baroreflex sensitivity. On the other hand, the present study showed that CVLM microinjection of L-ARG in the 2 K1C rats did not alter the already low sensitivity of the baroreflex, which may be related to the very low value for baroreflex sensitivity that these animals showed at the baseline. Interestingly, CVLM microinjection of L-NAME induced a significant improvement in the baroreflex bradycardia in hypertensive rats, in contrast to the effect in normotensive rats. This finding further suggests that endogenous NO may participate in the modulation of the baroreflex control of HR, at least in the CVLM of 2 K1C rats.
The inhibitory role of NO in baroreflex modulation at the CVLM could be due to one or more of the following mechanisms: (1) the well-known inhibitory GABAergic pathway from CVLM to RVLM [29, 31, 39, 64] , (2) the projection from the NTS to the CVLM [27, 65] , and (3) the projections from the CVLM to the nucleus ambiguus [66] . Future studies will be necessary to evaluate which pathways are being modulated by NO at the CVLM, especially considering that activation of the parasympathetic system is the major mechanism involved in baroreflex bradycardia.
In the present study, we have shown that CVLM microinjection of L-NAME induced similar decreases in MAP and HR in 2K1C and in normotensive rats. Accordingly, CVLM microinjection of L-ARG induced similar increases in BP in 2K1C and in normotensive rats. This agrees with previous studies by us [15] and others [14] , which showed that CVLM microinjection of L-ARG induced a significant increase in MAP, whereas L-NAME induced a significant hypotension. Shapoval et al. [14] showed that unilateral CVLM microinjections of sodium nitroprusside (an NO donor) and L-ARG in anesthetized cats produced an increase in MAP and RSNA activity, whereas microinjection of L-NMMA, a non-selective inhibitor of NOS isoforms, produced opposite effects. Similarly, Lage et al. [15] , observed that microinjection of L-NAME in the CVLM of normotensive rats produced hypotension, whereas microinjection of L-ARG promoted an increase in BP in normotensive rats.
Kishi et al. [54] showed in stroke-prone SHR that overexpression of an eNOS-related gene in the RVLM increases the release of both glutamate and GABA. However, the predominant effect was on GABAergic activity, which resulted in a reduction in the SNS activity in these animals. It has been reported that hypertension is accompanied by a decrease in the activity of CVLM gabaergic neurons that project to sympathetic neurons in the RVLM [39, 40, 68] . Taken together, the data from these studies suggest that NO has an inhibitory effect on neurons involved in the tonic control of arterial pressure, possibly by suppressing the CVLM-RVLM GABAergic pathway.
As mentioned before, our data showed that there was an increased baroreflex response to CVLM L-NAME microinjection in Values are mean ± SEM; n = number of samples. Each sample represents a pool of the CVLM of 2 animals. * p < 0.05 compared to the respective SHAM group (Student's t test).
hypertensive rats. However, 2K1C rats showed a similar BP effect after CVLM L-NAME microinjection compared with SHAM rats. These data suggest that sympathetic and cardiac baroreflex are independently regulated by distinct signaling system in the CVLM [34] Further, NO is specifically affecting the activity of neurons involved in baroreflex.
On the other hand, literature data have shown that during hypertension, oxidative stress also may increase the production of other free radicals such as the superoxide anion (O 2 À ), which is also considered a modulator of SNS activity [1] . Furthermore, the reaction between the superoxide anion and NO leads to production of another free radical, peroxynitrite, which also contributes to cardiac sympathovagal imbalance in hypertensive states [3] .
Our present data showed that CVLM microinjection of Vit C, which has the property of scavenging superoxide anions, did not alter baroreflex bradycardia in 2K1C or in SHAM rats. This suggests that endogenous superoxide anions are not involved in baroreflex modulation, at least at this brain site. Our data also showed that CVLM microinjection of Vit C caused significant hypotension and bradycardia only in the 2K1C rats. No cardiovascular effect was observed in normotensive rats after Vit C microinjection. Similarly, Oliveira-Sales et al. [1] reported that microinjection of Vit C into the RVLM lowered BP and HR only in 2K1C rats and not in SHAM rats, showing that oxidative stress is an important additional mechanism for the high BP of 2K1C rats. As mentioned above, it is interesting that Vit C microinjection did not alter baroreflex bradycardia in 2K1C or normotensive rats, which is in line with the concept that different pathways are involved in baseline MAP and reflex control of HR [34] , and superoxide may only affect one of them.
Furthermore, microinjection of L-NAME and Vit C in the CVLM induced similar effects on MAP and HR in 2K1C rats by inhibiting the formation of NO and the superoxide anion, respectively. Considering also that CVLM microinjection of Vit C did not alter the MAP of SHAM rats, our data suggest the involvement of superoxide anions in the CVLM in maintaining the high levels of MAP in 2K1C hypertensive rats.
In summary, our data emphasize the inhibitory role of NO in the CNS, by showing that NO in the CVLM may be an additional mechanism involved in the attenuated baroreflex bradycardia that is observed in renovascular hypertensive 2K1C rats. The data also showed that, during hypertension, there is an increased production of superoxide in the CVLM, which in turn would participate in maintaining high blood pressure in the 2K1C model. Overall, the data from the present study showed that increased oxidative stress in the CVLM contributes importantly to reducing the sensitivity of reflex bradycardia and to the high levels of MAP that occur in renovascular hypertension.
